Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

ZEPATIER

ELBASVIR; GRAZOPREVIR

Standard Dose
50MG;100MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview ZEPATIER is listed in Drugs@FDA under application 208261 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient ELBASVIR; GRAZOPREVIR Form and strength TABLET;ORAL - 50MG;100MG Sponsor MSD SUB MERCK Submission history Latest submission status date: 2021-12-09 00:00:00.

Structured Monograph

Clinical summary

Approval overview ZEPATIER is listed in Drugs@FDA under application 208261 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient ELBASVIR; GRAZOPREVIR Form and strength TABLET;ORAL - 50MG;100MG Sponsor MSD SUB MERCK Submission history Latest submission status date: 2021-12-09 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.